Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2021-04-06 M&A Activity
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
CellaVision förvärvar exklusiva rättigheter till ny mikroskopiteknologi
M&A Activity Classification · 1% confidence The document announces that CellaVision has signed an agreement to acquire exclusive rights to a new microscopy technology (Fourier Ptychographic Microscopy) for a cash consideration of 28.7 MSEK. This is a significant corporate action related to technology acquisition and intellectual property, which falls under the scope of corporate financing or strategic activity. Since it is an announcement about a specific transaction (acquisition of rights/IP) rather than a general capital change (SHA) or a takeover bid (TAR), it best fits the 'Capital/Financing Update' category, as it involves a material investment and change in asset structure. The final line confirms it is information CellaVision is obliged to disclose under EU Market Abuse Regulation, suggesting a regulatory announcement, but the content is highly specific to a strategic investment/acquisition. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for a technology acquisition payment, although 'RNS' (Regulatory Filings) is a possibility if the specific nature of the acquisition doesn't warrant a more specific category. However, acquisitions of key assets/IP are often grouped with financing/investment activities. I will classify it as CAP due to the explicit mention of the purchase price and strategic investment nature.
2021-04-06 Swedish
CellaVision AB: Notice of 2021 Annual General Meeting of CellaVision AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "CellaVision AB: Notice of 2021 Annual General Meeting of CellaVision AB (publ)" and repeatedly refers to the "Annual General Meeting (the "AGM")". It details the procedures for advance voting, the proposed agenda items (including election of chairman, board members, approval of remuneration report, and dividend proposal), and the required shareholder actions. This content directly corresponds to the materials distributed to shareholders in preparation for the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-03-26 English
CellaVision AB: Kallelse till årsstämma 2021 i CellaVision AB (publ)
AGM Information Classification · 1% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I CELLAVISION AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (PUBL)". It details the date (April 29, 2021), the procedure (via advance voting due to COVID-19), the agenda items (including election of the board, approval of remuneration report, and dividend proposal), and the required deadlines for participation. This content is the formal notification and associated materials for the Annual General Meeting (AGM). Therefore, the correct classification is AGM Information (AGM-R).
2021-03-26 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding for CellaVision AB by The Capital Group Companies, Inc. Specifically, it shows the 'Before the transaction' and 'After the transaction' share quantities, the reason for the notification ('Sell'), and the resulting percentage of voting rights (4.47766%). This structure perfectly matches the definition of a Major Shareholding Notification, which reports when an investor crosses ownership thresholds. The relevant code is MRQ.
2021-02-19 English
The Nomination Committee's proposal regarding the Board of CellaVision AB for the 2021 Annual General Meeting
Board/Management Information Classification · 1% confidence The document explicitly discusses the 'Nomination Committee's proposal regarding the Board of CellaVision AB for the 2021 Annual General Meeting (AGM)'. It details proposed directors, the proposed Chairman, and the date of the AGM (April 29, 2021). This content directly relates to the composition of the board and proposals presented for shareholder vote at the AGM. While it is a proposal *for* the AGM, the core subject matter is the nomination/board composition, which aligns most closely with Board/Management Information (MANG) or potentially Governance Information (CGR). However, since the context is specifically the proposal *for* the AGM regarding board composition, and it is not the final voting result (DVA) or the full proxy statement (PSI), MANG is a strong fit for management/board changes. Given the context of a proposal for the AGM regarding board composition, MANG (Board/Management Information) is the most appropriate classification, as it details proposed changes to the board structure.
2021-02-04 English
Valberedningens förslag rörande styrelse för CellaVision AB inför årsstämman 2021
Board/Management Information Classification · 1% confidence The document is titled "Valberedningens förslag rörande styrelse för CellaVision AB inför årsstämman 2021" (Nomination Committee's proposal regarding the board for CellaVision AB ahead of the 2021 Annual General Meeting). It details proposals for board members, including a new chairman, and mentions that the full proposal and justification will be available when the notice for the AGM is published. This content directly relates to the composition of the board and proposals to be voted on at the Annual General Meeting (AGM). This strongly aligns with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, or potentially 'Governance Information' (CGR) or 'Proxy Solicitation & Information Statement' (PSI), but the focus on the nomination committee's proposal for the AGM makes AGM-R the most precise fit for this specific pre-meeting material.
2021-02-04 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.